PDCD1 and neoplasm: By leveraging different approaches including the mRNA-4175/V940 therapy or tumor-infiltrating lymphocyte (TIL) therapy in combination with anti-PD-1 checkpoint inhibitors like pembrolizumab or nivolumab, anti-tumor immune responses can be enhanced.